FAZA PET乏氧与HPV状态对头颈鳞癌放疗结局的影响:DAHANCA 24试验长期结果
中位随访7.8年,9例出现局部区域复发,高摄取组复发风险显著高于低摄取组(HR 5.8)。乏氧且非OPCp16+肿瘤患者复发风险最高。
要点
- 治疗前FAZA PET/CT显示TMR≥1.6与头颈鳞癌放疗后治疗失败显著相关。
- 高摄取组局部区域复发风险显著高于低摄取组(HR 5.8)。
- 乏氧且非OPCp16+肿瘤患者复发风险最高,风险差异为45%。
核心结论
- 基线FAZA PET/CT TMR≥1.6的头颈鳞癌与根治性放疗后治疗失败显著相关。
- 除HPV/p16状态外,FAZA PET/CT有潜力筛选需要治疗强化的肿瘤。
研究设计与样本
- 前瞻性队列DAHANCA 24试验(NCT01017224),2009至2011年纳入38例完成根治性放疗的非转移性喉、口咽、下咽和鼻咽鳞癌患者。
- 复发经组织学证实,复发影像与治疗前FAZA PET/CT进行可变形融合,视觉比较空间信息。
主要发现
- 16例(42%)患者治疗前为高摄取肿瘤(TMR≥1.6)。
- 中位随访7.8年,共观察到9例局部区域复发,其中7例在高摄取组(44% vs 9%,HR 5.8 [1.2-28.2])。
- 乏氧且非OPCp16+肿瘤患者局部区域复发风险最高(57% [21-94%]),与乏氧较低的非OPCp16+肿瘤相比风险差异为45% [4-86%]。
- 8例复发影像足以与FAZA PET/CT共配准,其中6例原发肿瘤乏氧,2例复发与基线乏氧亚体积重叠。
关键数值与推荐
- 乏氧阈值:肿瘤-肌肉比值(TMR)≥1.6定义为高摄取/乏氧。
- 乏氧非OPCp16+肿瘤复发风险57%(21-94%),与乏氧较低非OPCp16+肿瘤风险差异45%(4-86%)。
临床怎么用
- FAZA PET/CT可用于头颈鳞癌放疗前乏氧评估,辅助识别高危患者。
- 结合HPV/p16状态,FAZA PET/CT有潜力指导治疗强化决策。
局限性
- 样本量较小(38例),复发事件少(9例),结果需更大样本验证。
- 仅8例复发患者有足够影像进行空间共配准分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Hypoxic tumor volumes can be visualized with 18F-FAZA PET/CT. In head and neck squamous cell carcinoma (HNSCC), hypoxia is important for the clinical outcome after primary radiotherapy (RT). The outcome is furthermore heavily influenced by the HPV/p16-positivity of oropharyngeal tumors (OPCp16+ tumors). The study purposes were (1) to report on locoregional failures within five years after primary RT in a prospective cohort stratified by both HPV/p16-status and PET hypoxia and (2) to characterize the failure site and the spatial association to PET hypoxia. MATERIAL AND METHODS: From 2009 to 2011, 38 patients with non-metastatic SCC of the larynx, oro-, hypo- and nasopharynx completing primary RT were included in the prospective DAHANCA 24 trial (NCT01017224). Fifteen patients had OPCp16+ tumors. All were imaged with a static FAZA PET/CT prior to treatment. The hypoxia threshold was determined by a tumor-to-muscle ratio (TMR) of 1.6. Recurrences were documented histologically. Imaging of the recurrence was deformable fused with the pre-treatment FAZA PET/CT. The spatial information of recurrence- and hypoxic volumes were compared visually. RESULTS: Sixteen patients had more hypoxic tumors (high tracer uptake, TMR ≥1.6) before treatment (42%). With a median follow-up of 7.8 years, nine locoregional recurrences were observed, of which seven were in patients with high-uptake tumors (44% and 9%, respectively, HR 5.8 [1.2-28.2]). The risk of locoregional recurrence was highest among patients with more hypoxic, non-OPCp16+ tumors (57% [21-94%]), with a risk difference of 45% [4-86%], when comparing to less hypoxic, non-OPCp16+ tumors. Eight patients had sufficient imaging of the recurrence for co-registration with the FAZA PET/CT. Six had hypoxic primary tumors, and in two, the recurrence was overlapping the baseline hypoxic subvolume. CONCLUSION: HNSCC demonstrating a TMR ≥1.6 at baseline is significantly associated with treatment failure after primary RT. In addition to HPV/p16-status, FAZA PET/CT has potential for the selection of tumors requiring treatment intensification.
引用
- Saksø M, Mortensen LS, Primdahl H, et al. Influence of FAZA PET hypoxia and HPV-status for the outcome of head and neck squamous cell carcinoma (HNSCC) treated with radiotherapy: Long-term results from the DAHANCA 24 trial (NCT01017224). Radiother Oncol. 2020. PMID: 32805273. doi:10.1016/j.radonc.2020.08.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。